Bristol-Myers Squibb Company (BMY)
| Market Cap | 125.59B +39.0% |
| Revenue (ttm) | 49.19B +3.1% |
| Net Income | 9.28B +83.8% |
| EPS | 4.54 +82.7% |
| Shares Out | 2.04B |
| PE Ratio | 13.53 |
| Forward PE | 10.08 |
| Dividend | $2.52 (4.10%) |
| Ex-Dividend Date | Oct 2, 2026 |
| Volume | 9,763,066 |
| Open | 62.66 |
| Previous Close | 63.00 |
| Day's Range | 61.31 - 62.84 |
| 52-Week Range | 42.52 - 68.64 |
| Beta | 0.18 |
| Analysts | Hold |
| Price Target | 65.42 (+6.41%) |
| Earnings Date | Oct 29, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $65.42, which is an increase of 6.41% from the latest price.
News
Bristol Myers tells Bloomberg aims to resume paused CAR-T trials in 2027
A Bristol Myers (BMY) spokesperson stated in an email to Bloomberg that the company has identified the cause of an earlier-observed CAR-T safety signal and that the company aims to…
Bristol Myers discloses death of CAR T patient in MS study
Bristol Myers (BMY) disclosed that one patient with highly active relapsing multiple sclerosis experienced a fatal event of septic pneumonia in its Phase 1 trial. Following zola-cel infusion, the pati...
Bristol Myers presents results from Phase 1 Breakfree-2 study
Bristol Myers (BMY) Squibb announced disclosure of interim safety and efficacy results from the multiple sclerosis cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zola...
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
Pathos AI secures $237M in Series E financing
Pathos AI announced the closing of a $237M Series E financing round at a post-money valuation of approximately $3B. The financing was led by Bristol Myers (BMY) Squibb, alongside participation…
Pathos AI enters collaborations with Bristol Myers, Tempus AI
Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease ...
Tempus AI expands collaboration with Bristol Myers
Tempus AI (TEM) announced a multi-year agreement with Bristol Myers Squibb (BMY), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insi...
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology ...
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing...
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (...
Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
Bristol Myers Squibb and partner SystImmune said on Friday their experimental breast cancer treatment slowed disease progression compared to standard chemotherapy in a late-stage study.
SystImmune, Bristol announce iza-bren reduced disease progression, death by 59%
SystImmune and Bristol Myers (BMY) Squibb announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical reported positive results from a prespecified interim analysis of the randomized Phas...
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced H...
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026.
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Bristol Phase 3 win underscores opportunity for GRI Bio, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $10 price target on GRI Bio (GRI) after Bristol Myers Squibb (BMY) reported data from its Phase 3 ALOFT-IPF trial of admilparant in…
Bristol Myers price target lowered to $60 from $65 at Wells Fargo
Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal Weight rating on the shares. The firm sees…
Bristol Myers price target raised to $76 from $73 at Jefferies
Jefferies analyst Akash Tewari raised the firm’s price target on Bristol Myers (BMY) to $76 from $73 and keeps a Buy rating on the shares after the company reported “positive”…
RBC says Bristol Myers’ ALOFT-IPF efficacy ‘encouraging, but confounding’
After Bristol Myers (BMY) announced positive topline results from both the Phase 3 ALOFT-IPF trial for admilparant in IPF and the ACTION-1 trial for RYZ101 in GEP-NETs, RBC Capital analyst…
Bristol Myers has blockbuster opportunity in IPF, says William Blair
William Blair keeps a Market Perform rating on Bristol Myers (BMY) after the company announced results from its Phase III study of admilparant in idiopathic pulmonary fibrosis. The trial met…
Bristol Myers tells Bloomberg admilparent death unlikely due to drug
Bristol Myers (BMY) told Bloomberg says the patient death in the admilparant’s study was unlikely due to the drug. The idiopathic pulmonary fibrosis patient was getting the higher dose of…
Bristol Phase 3 success with admilparant should send Contineum up, says Stifel
After Bristol Myers Squibb (BMY) announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant in adults with idiopathic pulmonary ...
Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial
Bristol Myers Squibb said on Monday a lower dose of its experimental drug slowed the progression of a serious lung-scarring disease, putting it on track to be a first-of-its-kind treatment if approv...